Company Profile

Suzhou PANOMIX Biomedical Tech Co., LTD (abbreviation: PANOMIX) was established in Suzhou Industrial Park in 2013. As a pioneer and leader in the field of life science research and medical health, PANOMIX focuses on the research and clinical application development of cutting-edge metabolomics technology, and is committed to becoming a complete solution provider of metabolomics precision medicine and precision nutrition, helping you support a healthy metabolism.

PANOMIX has set up several branches around the world, with a R&D and production base of more than 10,000 square meters, and the founding and core teams come from Harvard University, MD Anderson Cancer Center, UC Davis, Peking University, Chinese Academy of Sciences and other well-known universities and research institutes at home and abroad. The company has more than 80 sets of world-leading mass spectrometry equipment, can provide more than 100 detection and analysis services, more than 20 clinical testing products, and has a number of innovative product research and development pipelines, covering the diagnosis, early screening and medication guidance application of cardiovascular, stroke, tumor and intestinal microorganisms. The business segment covers scientific research services, industrial services, new drug services, clinical detection services, clinical products and health management, with a layout of universities, research institutes, hospitals and enterprises in 34 provinces, municipalities and autonomous regions, serving more than 1,000 customers.

With continuous R&D accumulation and technological innovation, the company has completed a number of international advanced metabolomics characteristic technologies and application research, through the establishment of untargeted metabolomics technology platform with independent intellectual property rights "Global untargeted metabolomics" and cloud data analysis system BioDeepTM, it has successfully created an integrated platform running through metabolomics, clinical products and big data analysis, has been rated as a leading enterprise in science and technology, high-tech enterprises, private science and technology enterprises in Jiangsu Province, etc. It has obtained ISO-9001 quality management system certification, CMA license, third-party medical inspection license, and more than 30 intellectual property rights, becoming an industry leader.

Since its establishment, PANOMIX has been widely concerned and recognized by the capital market, and has received multiple rounds of investment from well-known funds in the industry, such as YuanBio Venture Capital, Watson Investment, and BOHE Angel Fund. In the future, the company will accelerate its global layout, actively expand metabolomics technology innovation and clinical application, and promote the development of the pharmaceutical industry.

Development History